Pharma major Dr Reddy’s Laboratories is likely to post around 13-16 per cent increase in net profit at about ₹1,450 crore in the second quarter of the current fiscal ending September 30, 2025.

The company is scheduled to announce its Q2 results today.

The analysts peg revenue growth at 8 to 9 per cent, in the range of ₹8,600 crore to 8,800 crore driven by Indian and European markets with a likely drag in the US market. Margins are expected to hover around 25 per cent.

Headwinds are expected with tapering of Revlimid revenues and continuation pricing pressure Margins are expected to stay near the 25 per cent mark, supported by mix improvement and currency tailwinds, even as pricing pressure weighs on profitability.

The Hyderabad based drug-maker’s net profit declined 9 per cent at ₹1

See Full Page